 |
|||
Kaiser Permanente's Care Management Institute Receives AHIP Innovation and Excellence in Chronic Care Award
Kaiser Permanente's Care Management Institute (KP CMI) is the recipient of the AHIP Innovation and Excellence in Chronic Care Award in the large affiliated category. The award was presented for the A-L-L (aspirin-Lisinopril-lovastatin) Initiative. The A-L-L Initiative demonstrates the rapid and widespread adoption of successful strategies to prevent adverse cardiovascular events among members with coronary artery disease and diabetes. The initiative was developed in response to rigorous clinical studies and simulation modeling by Archimedes that demonstrated a significant potential for reduced morbidity and mortality among individuals at risk for myocardial infarction and stroke. The treatment strategy includes simple protocols of three classes of fixed-dose generic medications: aspirin, cholesterol-lowering drugs called statins, and blood pressure medication called ACE-inhibitors (Lisinopril.) Also gaining recognition from AHIP is Kaiser Permanente HealthConnect. KP HC was a finalist for the AHIP Foundation's Innovation and Excellence Award in Health Information Technology. The Innovation in Chronic Care Award recognizes member organizations for their successful efforts to improve the management of chronic disease through innovative models of care. A successful model ensures continuity, coordination, and monitoring of one or more chronic conditions and provides care that contributes to superior clinical outcomes, enhances quality of life, and reduces the risk of preventable disability. Karen Ignagni, President and CEO of AHIP, said the recipients of the awards have demonstrated effective leadership in their communities and the health care field. "The award recipients embody the spirit of our industry by pioneering successful health care innovations and investing in unique education and community action programs," said Ignagni. "Their commitment to the consumers and communities they serve make everyone involved proud to be a part of the health plan community." "The award is really recognition of the current and future benefits that have or will be delivered from implementing this program," said William Caplan, MD, CMI's interim executive director. "Success to date is due to the hard work and commitment of hundreds of people in the regions who are dedicated to improving the health outcomes and quality of life for people at risk for cardiovascular disease."
Accepting the award are... He then asked the crowd to "envision your friends and family members with diabetes or heart disease standing in front of the sink tomorrow morning with a glass of water. Then envision them putting three pills in their mouth: an aspirin, a blood pressure bill called Lisinopril, and a cholesterol-lowering medication -- a statin, specifically lovastatin. If they do that every morning they will have a 71% less chance of having a heart attack or stroke." "That's ALL there is to it," Dr. Dudl stated. He added that the cost per person would be about $10 per month and would return $300 per month to the health care system. "And do you think it would be good for the 46 million uninsured," Dr. Dudl asked the crowd? "We think so, and in that regard, have just given a grant to a community clinic to test how that may work. If you think that is a good idea, come join us in doing this!" After the ceremony, Dr. Dudl said he wanted to express his appreciation "to CMI for leading this effort, to the ALL champions in the regions who made it happen, and to the regions themselves for their quick implementation. |
|||
In accepting the AHIP Innovation and Excellence in Chronic Care Award for the Care Management Institute, Jim Dudl, MD, thanked "all the Kaiser Permanente people who implemented the A-L-L (aspirin-lovastatin-lisinopril) Program." Dr. Dudl, CMI's clinical lead for diabetes, and Michelle Wong, CMI's Care Management Consultant for diabetes, led the interregional A-L-L Initiative.